Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
About Pharmos
Pharmos discovers and develops novel therapeutics to treat a range of indications including neurological and inflammatory disorders. The Company’s core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is undergoing Phase II testing in pain. Other compounds from Pharmos’ proprietary synthetic cannabinoid library are in pre-clinical studies targeting pain, multiple sclerosis, rheumatoid arthritis and other disorders. ( www.pharmoscorp.com )
Pharmos Corporation
99 Wood Avenue South Suite 311
Iselin, New Jersey 08830
USA
Tel: (732) 452-9556
Fax: (732) 452-9557